Total National Institutes of Health research expenditure for childhood obesity, approximately $250 million in 2022, pales in comparison to the investments of the pharmaceutical industry.Įven so, the physiologic actions of antiobesity drugs and surgery may have similarities to diet, among which a low–glycemic load diet (reduced in carbohydrate or glycemic index) shows promise ( Table). However, few high-quality studies of scope and rigor comparable to that of a phase 3 drug trial have ever been conducted to test novel dietary obesity treatment in any age group. Evidence-based reviews such as the guideline must, of course, base recommendations on available evidence, and the results for weight loss obtained with drugs and surgical procedures seem superior to those for diet. This emphasis does not indicate a bias or oversight of the guideline committee per se. Diet received relatively little specific attention beyond advice to follow the US Department of Agriculture’s MyPlate recommendations and limit intake of sugar-sweetened beverages. 1 This guideline emphasizes weight loss drugs and bariatric surgery even though the prevalence of childhood obesity has increased far too fast to be attributable to otherwise untreatable genetic predisposition. Earlier this year, the American Academy of Pediatrics (AAP) published a clinical practice guideline for the evaluation and treatment of children with obesity. Treatment focused on the root cause of disease generally achieves the best outcomes for efficacy and safety, a precept that has guided medical research and clinical practice for centuries. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine. ![]() Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |